Where to Buy NAD+: Pharmaceutical Grade or Food Grade

Where to buy NAD+ has five real answers, and sorting them by price produces a ranking that gets the risk exactly backwards. The channel that charges the most is not the one with the best analytical record, and the channel with the worst record is the one most buyers assume is supervised.

The variable that actually separates them is grade: whether the underlying material was manufactured and released as a pharmaceutical ingredient or as a food ingredient, and whether anyone in the chain can tell you which. FDA has documented that question being answered wrongly inside licensed compounding pharmacies, which sets a useful floor for how much confidence to place in channels with less oversight than that.

One vendor is disclosed below because its published documents and commitments can be quoted precisely. Everything else in this article is described by category.

Where to buy NAD+: the five channels side by side

The evidence column is the one that reorders the table. Cost and convenience follow from the channel structure rather than driving it.

Channel 1: research suppliers, where the document is yours to read

This channel has one structural advantage over every other and it is easy to overlook: you hold the container and you can ask for the paperwork before you pay. Nobody else in this comparison offers that. A clinic hands you an outcome, a pharmacy hands you a preparation, and only here does the analytical record sit in your hands with a lot number on it.

The advantage is worth exactly as much as the record behind it. Certificates in this market default to an identity and purity panel, typically HPLC with a mass spectrometry identity confirmation, because that is what the compound sold alongside NAD+ needs. That panel does not include a bacterial endotoxin result, and for this substance the endotoxin result is the one that has mattered in practice. Ask for it by name, in writing, before ordering.

Note also that NAD+ is sold here in gram quantities rather than in the five to ten milligram vials the peptide catalogue runs on, which is why we quote per 100 mg. The vendor disclosed above lists NAD+ 1,000 mg at $104.00 and halves that to $52.00 with the code PEPTIDEDECK, and publishes certificates from two independent laboratories per lot as a catalogue wide practice. What we cannot confirm from outside is whether the certificate for a given NAD+ lot carries an endotoxin line, and we say so rather than assuming it. Our seven point purchase checklist sets out how to put that question so it gets a real answer.

Channel 2: IV clinics and drip bars, where the record is two steps away

NAD+ has something the research peptide market does not: an open, advertised clinical retail channel. Wellness clinics, drip bars and med spas sell infusions publicly, at a large multiple of what the raw material costs, and they market them for a long list of conditions we report without adopting.

This is also the channel FDA wrote about. The agency stated it is aware of compounders using food grade NAD+ sold by repackagers to make intravenous products, that ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing due to the high risk of contamination with microbes and endotoxins, and that it has received adverse event reports following use of NAD+ injectable drugs including severe chills, shaking, vomiting and fatigue with some requiring medical treatment, reactions the agency describes as consistent with excessive levels of endotoxins.

The structural problem for a customer is distance. You are not the pharmacy’s customer; the clinic is. Two links separate you from the material record, and the default service model does not surface it. That is fixable by asking, and the questions are specific: which pharmacy compounded this, was the bulk substance pharmaceutical grade, and does the pharmacy hold an endotoxin result for it. This is also where a search for where to buy NAD+ injection usually lands, and it is worth noticing that such a search is asking for a prepared, administered product rather than for material, which is a different purchase with a different set of people accountable for it. What clinics charge and how the packages are structured is covered in our guide to local NAD+ clinics.

Channel 3: compounding pharmacies, and the category people get wrong

Compounded NAD+ is a real route, which surprises readers who have been told the opposite. On FDA’s list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026, the entry Nicotinamide Adenine Dinucleotide (NAD) sits in category 1, described as bulk drug substances under evaluation. The reduced form, listed as Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH), is in the same category.

Category 1 has a precise meaning and it is not approval. In FDA’s own words, the agency does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met. It is an interim enforcement posture adopted to avoid disrupting patient treatment while the substance is evaluated, and the list is explicitly under evaluation rather than settled. Anyone citing category 1 as evidence that NAD+ has been vetted has read it backwards.

There is a trap adjacent to this worth naming. A separate entry, Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate, appears in category 3, nominated without adequate supporting information for FDA to evaluate it. Substances in category 3 are not eligible for the category 1 policy. The names look like the same thing under different conventions and the categories are not the same, so a citation to one is not a citation to the other.

The genuinely useful detail in this channel is what 503A requires of the ingredient. Bulk drug substances used in compounding must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA under section 510 of the FD&C Act. That is a documentary standard a research buyer can borrow wholesale: certificate present, manufacturer identifiable. The full regulatory picture is set out in our explainer on NAD+ without a prescription.

Channel 4: overseas marketplaces and bulk brokers

Much of the material circulating in the other channels originates here, in kilogram listings on international trade platforms, and the unit prices reflect that position in the chain. Two problems recur and neither is about the compound being fake.

The first is documentary. The certificate offered is typically a product line document rather than one tied to a lot, which severs the connection between the analysis and the material in transit. The second is that grade is precisely the thing this channel is least motivated to clarify, since the same powder can be sold into food, cosmetic and research markets and the buyer specifies the application. FDA’s request that repackagers clearly label ingredients intended for foods or dietary supplements exists because that clarity is currently missing.

For a reader asking where to buy NAD+ at the lowest possible unit price, this is the honest answer, with the caveat that the saving is paid in evidence, recourse and time. The transaction mechanics, including what customs and payment method reveal, are covered in our end to end walkthrough of ordering online.

Channel 5: the supplement aisle, which sells something else

Search results for where to buy NAD+ return a large number of oral products, and most of them are not NAD+. They are precursors: nicotinamide mononucleotide and nicotinamide riboside, compounds cells convert along the salvage pathway toward NAD+. They are a different format, a different regulatory history and a different purchase, and we do not state their regulatory status here because it was not verified for this article.

On evidence grading, the precursor literature is where most of the in vivo work sits, and a substantial share of it is animal work rather than human trials. A widely cited 2018 review in Cell Metabolism surveyed the in vivo evidence for NAD boosting molecules and is a reasonable place to see how much of the case rests on preclinical models. Treat that as a reason to keep the two purchases separate rather than as a verdict on either.

Which channel answers the grade question fastest

Ranked on the single question this article is built around, the order is not the order of perceived legitimacy. The compounding pharmacy is bound by an explicit documentary requirement and is accountable for meeting it. The research supplier can answer directly and immediately, if it has commissioned the work, and you can hold the answer. The clinic can answer only by relaying, and typically has not been asked. The marketplace has a commercial reason not to answer at all. The supplement aisle is not answering the same question.

For most readers the practical choice is between the first and third of those, and the deciding factor is whether you want the paperwork in your hands or a clinician administering something whose paperwork sits elsewhere. If you want the criteria for choosing within the research channel, our weighted ranking method states its scoring rules before it produces a result, and our listing anatomy guide covers what a real product page states and a repackaged one omits.